phasefolio

get_methodology

Read-onlyIdempotent

Fetch a PhaseFolio methodology section's full content (rNPV model, backtest, PoS calibration, IRA framework, development paths, deal-term modelling, holding valuation, clinical stage normalization, evidence standards, network benchmarks, COGS benchmark, SG&A benchmark, tax benchmark, SEC EDGAR deal-term extraction). Designed for citation: each section has a stable URL and a methodology version identifier you can reference in analysis output.

Input Schema

TableJSON Schema

Name	Required	Description	Default
`section`	Yes	Which methodology section to fetch. 'rnpv' covers the core risk-adjusted NPV calculation: cumulative PoS, midpoint-discounted risk-adjusted development costs, the S-curve ramp/plateau/LOE revenue lifecycle net of COGS/SG&A/tax, WACC discounting, the rNPV and Unadjusted-NPV equations, Monte Carlo / expected NPV, and one-at-a-time sensitivity; 'backtest' covers the validation methodology and AUC/CI numbers; 'pos-calibration' covers the indication × modality × biomarker matrix, expanded modality normalization into the eight benchmark baselines, the scored multipliers including the model 2.6.0 biomarker_quality drug-specific multiplier (oncology solid tumor, Phase II/III), the Phase 1 ORR extracted-but-not-scored signal with its Phase 0 governance disclosure, and the non-scored drug-specific risk flags; 'ira-framework' covers the Year-9/Year-13 MFP cliff modeling and the separate IRA classification for expanded modalities such as RNA Therapeutics, Protein Degrader, Radioligand, Oncolytic Virus, and Cancer Vaccine; 'development-paths' covers development-path tiers, automatic-effect policy, and the no path-based PoS/default-multiplier rule; 'deal-term-modelling' covers how licensing deal terms map onto a scenario's deal structure (term-model mapping v1): what is modelled, not modelled and refused, the territory restriction and the approximations it names, milestone timing at stage ends, the cost-share rule, and the non-USD conversion-rate refusal; 'holding-valuation' covers how a Workspace holding is valued (scenario, share of asset value, look-through estimate, cost, not valued): each method's inputs, reason codes and completeness, the totals rules (never added across bases or currencies, estimates left out by default) and what the look-through estimate ignores; 'stage-normalization' covers exact clinical labels, work packages, canonical PoS gates, and the no label-only PoS modifier rule for Phase 1b/2a/2b, adaptive, pivotal, expansion, platform, bridging, and related labels; 'evidence-standards' covers source tiers and freshness rules; 'network-benchmarks' covers anonymization and cohort cuts; 'cogs-benchmark' covers the per-modality COGS% default bands and price-sensitivity methodology; 'sga-benchmark' covers the per-commercial-model SG&A% default bands (orphan/specialty/primary-care); 'tax-benchmark' covers the US-statutory-21% default tax rate, effective-rate reality, and the NOL cap; 'sec-deal-terms' is the retirement notice for the SEC EDGAR deal-term source (retired 2026-09-27), with its frozen versions.

Output Schema

TableJSON Schema

Name	Required	Description	Default
`data`	Yes

Schema Changelog

Changes observed during successful MCP inspections.

Changed3 schema fields changedSep 28, 2026

changedInput schema / properties / section / description

Previous value: -"Which methodology section to fetch. 'rnpv' covers the core risk-adjusted NPV calculation: cumulative PoS, midpoint-discounted risk-adjusted development costs, the S-curve ramp/plateau/LOE revenue lifecycle net of COGS/SG&A/tax, WACC discounting, the rNPV and Unadjusted-NPV equations, Monte Carlo / expected NPV, and one-at-a-time sensitivity; 'backtest' covers the validation methodology and AUC/CI numbers; 'pos-calibration' covers the indication × modality × biomarker matrix, expanded modality normalization into the eight benchmark baselines, the scored multipliers including the model 2.6.0 biomarker_quality drug-specific multiplier (oncology solid tumor, Phase II/III), the Phase 1 ORR extracted-but-not-scored signal with its Phase 0 governance disclosure, and the non-scored drug-specific risk flags; 'ira-framework' covers the Year-9/Year-13 MFP cliff modeling and the separate IRA classification for expanded modalities such as RNA Therapeutics, Protein Degrader, Radioligand, Oncolytic Virus, and Cancer Vaccine; 'development-paths' covers development-path tiers, automatic-effect policy, and the no path-based PoS/default-multiplier rule; 'deal-term-modelling' covers how licensing deal terms map onto a scenario's deal structure (term-model mapping v1): what is modelled, not modelled and refused, the territory restriction and the approximations it names, milestone timing at stage ends, the cost-share rule, and the non-USD conversion-rate refusal; 'stage-normalization' covers exact clinical labels, work packages, canonical PoS gates, and the no label-only PoS modifier rule for Phase 1b/2a/2b, adaptive, pivotal, expansion, platform, bridging, and related labels; 'evidence-standards' covers source tiers and freshness rules; 'network-benchmarks' covers anonymization and cohort cuts; 'cogs-benchmark' covers the per-modality COGS% default bands and price-sensitivity methodology; 'sga-benchmark' covers the per-commercial-model SG&A% default bands (orphan/specialty/primary-care); 'tax-benchmark' covers the US-statutory-21% default tax rate, effective-rate reality, and the NOL cap; 'sec-deal-terms' is the retirement notice for the SEC EDGAR deal-term source (retired 2026-09-27), with its frozen versions."New value: +"Which methodology section to fetch. 'rnpv' covers the core risk-adjusted NPV calculation: cumulative PoS, midpoint-discounted risk-adjusted development costs, the S-curve ramp/plateau/LOE revenue lifecycle net of COGS/SG&A/tax, WACC discounting, the rNPV and Unadjusted-NPV equations, Monte Carlo / expected NPV, and one-at-a-time sensitivity; 'backtest' covers the validation methodology and AUC/CI numbers; 'pos-calibration' covers the indication × modality × biomarker matrix, expanded modality normalization into the eight benchmark baselines, the scored multipliers including the model 2.6.0 biomarker_quality drug-specific multiplier (oncology solid tumor, Phase II/III), the Phase 1 ORR extracted-but-not-scored signal with its Phase 0 governance disclosure, and the non-scored drug-specific risk flags; 'ira-framework' covers the Year-9/Year-13 MFP cliff modeling and the separate IRA classification for expanded modalities such as RNA Therapeutics, Protein Degrader, Radioligand, Oncolytic Virus, and Cancer Vaccine; 'development-paths' covers development-path tiers, automatic-effect policy, and the no path-based PoS/default-multiplier rule; 'deal-term-modelling' covers how licensing deal terms map onto a scenario's deal structure (term-model mapping v1): what is modelled, not modelled and refused, the territory restriction and the approximations it names, milestone timing at stage ends, the cost-share rule, and the non-USD conversion-rate refusal; 'holding-valuation' covers how a Workspace holding is valued (scenario, share of asset value, look-through estimate, cost, not valued): each method's inputs, reason codes and completeness, the totals rules (never added across bases or currencies, estimates left out by default) and what the look-through estimate ignores; 'stage-normalization' covers exact clinical labels, work packages, canonical PoS gates, and the no label-only PoS modifier rule for Phase 1b/2a/2b, adaptive, pivotal, expansion, platform, bridging, and related labels; 'evidence-standards' covers source tiers and freshness rules; 'network-benchmarks' covers anonymization and cohort cuts; 'cogs-benchmark' covers the per-modality COGS% default bands and price-sensitivity methodology; 'sga-benchmark' covers the per-commercial-model SG&A% default bands (orphan/specialty/primary-care); 'tax-benchmark' covers the US-statutory-21% default tax rate, effective-rate reality, and the NOL cap; 'sec-deal-terms' is the retirement notice for the SEC EDGAR deal-term source (retired 2026-09-27), with its frozen versions."

changedInput schema / properties / section / enum

Previous value: -[
-  "rnpv",
-  "backtest",
-  "pos-calibration",
-  "ira-framework",
-  "development-paths",
-  "deal-term-modelling",
-  "stage-normalization",
-  "evidence-standards",
-  "network-benchmarks",
-  "cogs-benchmark",
-  "sga-benchmark",
-  "tax-benchmark",
-  "sec-deal-terms"
-]New value: +[
+  "rnpv",
+  "backtest",
+  "pos-calibration",
+  "ira-framework",
+  "development-paths",
+  "deal-term-modelling",
+  "holding-valuation",
+  "stage-normalization",
+  "evidence-standards",
+  "network-benchmarks",
+  "cogs-benchmark",
+  "sga-benchmark",
+  "tax-benchmark",
+  "sec-deal-terms"
+]

changedOutput schema / properties / data / properties / section_id / enum

Previous value: -[
-  "rnpv",
-  "backtest",
-  "pos-calibration",
-  "ira-framework",
-  "development-paths",
-  "deal-term-modelling",
-  "evidence-standards",
-  "network-benchmarks",
-  "cogs-benchmark",
-  "sga-benchmark",
-  "tax-benchmark",
-  "sec-deal-terms"
-]New value: +[
+  "rnpv",
+  "backtest",
+  "pos-calibration",
+  "ira-framework",
+  "development-paths",
+  "deal-term-modelling",
+  "holding-valuation",
+  "evidence-standards",
+  "network-benchmarks",
+  "cogs-benchmark",
+  "sga-benchmark",
+  "tax-benchmark",
+  "sec-deal-terms"
+]

Changed1 schema field changedSep 28, 2026

changedInput schema / properties / section / description

Previous value: -"Which methodology section to fetch. 'rnpv' covers the core risk-adjusted NPV calculation: cumulative PoS, midpoint-discounted risk-adjusted development costs, the S-curve ramp/plateau/LOE revenue lifecycle net of COGS/SG&A/tax, WACC discounting, the rNPV and Unadjusted-NPV equations, Monte Carlo / expected NPV, and one-at-a-time sensitivity; 'backtest' covers the validation methodology and AUC/CI numbers; 'pos-calibration' covers the indication × modality × biomarker matrix, expanded modality normalization into the eight benchmark baselines, the scored multipliers including the engine 2.6.0 biomarker_quality drug-specific multiplier (oncology solid tumor, Phase II/III), the Phase 1 ORR extracted-but-not-scored signal with its Phase 0 governance disclosure, and the non-scored drug-specific risk flags; 'ira-framework' covers the Year-9/Year-13 MFP cliff modeling and the separate IRA classification for expanded modalities such as RNA Therapeutics, Protein Degrader, Radioligand, Oncolytic Virus, and Cancer Vaccine; 'development-paths' covers development-path tiers, automatic-effect policy, and the no path-based PoS/default-multiplier rule; 'deal-term-modelling' covers how licensing deal terms map onto a scenario's deal structure (term-model mapping v1): what is modelled, not modelled and refused, the territory restriction and the approximations it names, milestone timing at stage ends, the cost-share rule, and the non-USD conversion-rate refusal; 'stage-normalization' covers exact clinical labels, work packages, canonical PoS gates, and the no label-only PoS modifier rule for Phase 1b/2a/2b, adaptive, pivotal, expansion, platform, bridging, and related labels; 'evidence-standards' covers source tiers and freshness rules; 'network-benchmarks' covers anonymization and cohort cuts; 'cogs-benchmark' covers the per-modality COGS% default bands and price-sensitivity methodology; 'sga-benchmark' covers the per-commercial-model SG&A% default bands (orphan/specialty/primary-care); 'tax-benchmark' covers the US-statutory-21% default tax rate, effective-rate reality, and the NOL cap; 'sec-deal-terms' is the retirement notice for the SEC EDGAR deal-term source (retired 2026-09-27), with its frozen versions."New value: +"Which methodology section to fetch. 'rnpv' covers the core risk-adjusted NPV calculation: cumulative PoS, midpoint-discounted risk-adjusted development costs, the S-curve ramp/plateau/LOE revenue lifecycle net of COGS/SG&A/tax, WACC discounting, the rNPV and Unadjusted-NPV equations, Monte Carlo / expected NPV, and one-at-a-time sensitivity; 'backtest' covers the validation methodology and AUC/CI numbers; 'pos-calibration' covers the indication × modality × biomarker matrix, expanded modality normalization into the eight benchmark baselines, the scored multipliers including the model 2.6.0 biomarker_quality drug-specific multiplier (oncology solid tumor, Phase II/III), the Phase 1 ORR extracted-but-not-scored signal with its Phase 0 governance disclosure, and the non-scored drug-specific risk flags; 'ira-framework' covers the Year-9/Year-13 MFP cliff modeling and the separate IRA classification for expanded modalities such as RNA Therapeutics, Protein Degrader, Radioligand, Oncolytic Virus, and Cancer Vaccine; 'development-paths' covers development-path tiers, automatic-effect policy, and the no path-based PoS/default-multiplier rule; 'deal-term-modelling' covers how licensing deal terms map onto a scenario's deal structure (term-model mapping v1): what is modelled, not modelled and refused, the territory restriction and the approximations it names, milestone timing at stage ends, the cost-share rule, and the non-USD conversion-rate refusal; 'stage-normalization' covers exact clinical labels, work packages, canonical PoS gates, and the no label-only PoS modifier rule for Phase 1b/2a/2b, adaptive, pivotal, expansion, platform, bridging, and related labels; 'evidence-standards' covers source tiers and freshness rules; 'network-benchmarks' covers anonymization and cohort cuts; 'cogs-benchmark' covers the per-modality COGS% default bands and price-sensitivity methodology; 'sga-benchmark' covers the per-commercial-model SG&A% default bands (orphan/specialty/primary-care); 'tax-benchmark' covers the US-statutory-21% default tax rate, effective-rate reality, and the NOL cap; 'sec-deal-terms' is the retirement notice for the SEC EDGAR deal-term source (retired 2026-09-27), with its frozen versions."

Changed3 schema fields changedSep 27, 2026

changedInput schema / properties / section / description

Previous value: -"Which methodology section to fetch. 'rnpv' covers the core risk-adjusted NPV calculation: cumulative PoS, midpoint-discounted risk-adjusted development costs, the S-curve ramp/plateau/LOE revenue lifecycle net of COGS/SG&A/tax, WACC discounting, the rNPV and Unadjusted-NPV equations, Monte Carlo / expected NPV, and one-at-a-time sensitivity; 'backtest' covers the validation methodology and AUC/CI numbers; 'pos-calibration' covers the indication × modality × biomarker matrix, expanded modality normalization into the eight benchmark baselines, the scored multipliers including the engine 2.6.0 biomarker_quality drug-specific multiplier (oncology solid tumor, Phase II/III), the Phase 1 ORR extracted-but-not-scored signal with its Phase 0 governance disclosure, and the non-scored drug-specific risk flags; 'ira-framework' covers the Year-9/Year-13 MFP cliff modeling and the separate IRA classification for expanded modalities such as RNA Therapeutics, Protein Degrader, Radioligand, Oncolytic Virus, and Cancer Vaccine; 'development-paths' covers development-path tiers, automatic-effect policy, and the no path-based PoS/default-multiplier rule; 'stage-normalization' covers exact clinical labels, work packages, canonical PoS gates, and the no label-only PoS modifier rule for Phase 1b/2a/2b, adaptive, pivotal, expansion, platform, bridging, and related labels; 'evidence-standards' covers source tiers and freshness rules; 'network-benchmarks' covers anonymization and cohort cuts; 'cogs-benchmark' covers the per-modality COGS% default bands and price-sensitivity methodology; 'sga-benchmark' covers the per-commercial-model SG&A% default bands (orphan/specialty/primary-care); 'tax-benchmark' covers the US-statutory-21% default tax rate, effective-rate reality, and the NOL cap; 'sec-deal-terms' is the retirement notice for the SEC EDGAR deal-term source (retired 2026-09-27), with its frozen versions."New value: +"Which methodology section to fetch. 'rnpv' covers the core risk-adjusted NPV calculation: cumulative PoS, midpoint-discounted risk-adjusted development costs, the S-curve ramp/plateau/LOE revenue lifecycle net of COGS/SG&A/tax, WACC discounting, the rNPV and Unadjusted-NPV equations, Monte Carlo / expected NPV, and one-at-a-time sensitivity; 'backtest' covers the validation methodology and AUC/CI numbers; 'pos-calibration' covers the indication × modality × biomarker matrix, expanded modality normalization into the eight benchmark baselines, the scored multipliers including the engine 2.6.0 biomarker_quality drug-specific multiplier (oncology solid tumor, Phase II/III), the Phase 1 ORR extracted-but-not-scored signal with its Phase 0 governance disclosure, and the non-scored drug-specific risk flags; 'ira-framework' covers the Year-9/Year-13 MFP cliff modeling and the separate IRA classification for expanded modalities such as RNA Therapeutics, Protein Degrader, Radioligand, Oncolytic Virus, and Cancer Vaccine; 'development-paths' covers development-path tiers, automatic-effect policy, and the no path-based PoS/default-multiplier rule; 'deal-term-modelling' covers how licensing deal terms map onto a scenario's deal structure (term-model mapping v1): what is modelled, not modelled and refused, the territory restriction and the approximations it names, milestone timing at stage ends, the cost-share rule, and the non-USD conversion-rate refusal; 'stage-normalization' covers exact clinical labels, work packages, canonical PoS gates, and the no label-only PoS modifier rule for Phase 1b/2a/2b, adaptive, pivotal, expansion, platform, bridging, and related labels; 'evidence-standards' covers source tiers and freshness rules; 'network-benchmarks' covers anonymization and cohort cuts; 'cogs-benchmark' covers the per-modality COGS% default bands and price-sensitivity methodology; 'sga-benchmark' covers the per-commercial-model SG&A% default bands (orphan/specialty/primary-care); 'tax-benchmark' covers the US-statutory-21% default tax rate, effective-rate reality, and the NOL cap; 'sec-deal-terms' is the retirement notice for the SEC EDGAR deal-term source (retired 2026-09-27), with its frozen versions."

changedInput schema / properties / section / enum

Previous value: -[
-  "rnpv",
-  "backtest",
-  "pos-calibration",
-  "ira-framework",
-  "development-paths",
-  "stage-normalization",
-  "evidence-standards",
-  "network-benchmarks",
-  "cogs-benchmark",
-  "sga-benchmark",
-  "tax-benchmark",
-  "sec-deal-terms"
-]New value: +[
+  "rnpv",
+  "backtest",
+  "pos-calibration",
+  "ira-framework",
+  "development-paths",
+  "deal-term-modelling",
+  "stage-normalization",
+  "evidence-standards",
+  "network-benchmarks",
+  "cogs-benchmark",
+  "sga-benchmark",
+  "tax-benchmark",
+  "sec-deal-terms"
+]

changedOutput schema / properties / data / properties / section_id / enum

Previous value: -[
-  "rnpv",
-  "backtest",
-  "pos-calibration",
-  "ira-framework",
-  "development-paths",
-  "evidence-standards",
-  "network-benchmarks",
-  "cogs-benchmark",
-  "sga-benchmark",
-  "tax-benchmark",
-  "sec-deal-terms"
-]New value: +[
+  "rnpv",
+  "backtest",
+  "pos-calibration",
+  "ira-framework",
+  "development-paths",
+  "deal-term-modelling",
+  "evidence-standards",
+  "network-benchmarks",
+  "cogs-benchmark",
+  "sga-benchmark",
+  "tax-benchmark",
+  "sec-deal-terms"
+]

Changed1 schema field changedSep 27, 2026

changedInput schema / properties / section / description

Previous value: -"Which methodology section to fetch. 'rnpv' covers the core risk-adjusted NPV calculation: cumulative PoS, midpoint-discounted risk-adjusted development costs, the S-curve ramp/plateau/LOE revenue lifecycle net of COGS/SG&A/tax, WACC discounting, the rNPV and Unadjusted-NPV equations, Monte Carlo / expected NPV, and one-at-a-time sensitivity; 'backtest' covers the validation methodology and AUC/CI numbers; 'pos-calibration' covers the indication × modality × biomarker matrix, expanded modality normalization into the eight benchmark baselines, the scored multipliers including the engine 2.6.0 biomarker_quality drug-specific multiplier (oncology solid tumor, Phase II/III), the Phase 1 ORR extracted-but-not-scored signal with its Phase 0 governance disclosure, and the non-scored drug-specific risk flags; 'ira-framework' covers the Year-9/Year-13 MFP cliff modeling and the separate IRA classification for expanded modalities such as RNA Therapeutics, Protein Degrader, Radioligand, Oncolytic Virus, and Cancer Vaccine; 'development-paths' covers development-path tiers, automatic-effect policy, and the no path-based PoS/default-multiplier rule; 'stage-normalization' covers exact clinical labels, work packages, canonical PoS gates, and the no label-only PoS modifier rule for Phase 1b/2a/2b, adaptive, pivotal, expansion, platform, bridging, and related labels; 'evidence-standards' covers source tiers and freshness rules; 'network-benchmarks' covers anonymization and cohort cuts; 'cogs-benchmark' covers the per-modality COGS% default bands and price-sensitivity methodology; 'sga-benchmark' covers the per-commercial-model SG&A% default bands (orphan/specialty/primary-care); 'tax-benchmark' covers the US-statutory-21% default tax rate, effective-rate reality, and the NOL cap; 'sec-deal-terms' covers the SEC EDGAR 8-K Item 1.01 deal-term extraction pipeline (cohort, extractor + classifier versions, fields extracted, v0 vs v1 scope)."New value: +"Which methodology section to fetch. 'rnpv' covers the core risk-adjusted NPV calculation: cumulative PoS, midpoint-discounted risk-adjusted development costs, the S-curve ramp/plateau/LOE revenue lifecycle net of COGS/SG&A/tax, WACC discounting, the rNPV and Unadjusted-NPV equations, Monte Carlo / expected NPV, and one-at-a-time sensitivity; 'backtest' covers the validation methodology and AUC/CI numbers; 'pos-calibration' covers the indication × modality × biomarker matrix, expanded modality normalization into the eight benchmark baselines, the scored multipliers including the engine 2.6.0 biomarker_quality drug-specific multiplier (oncology solid tumor, Phase II/III), the Phase 1 ORR extracted-but-not-scored signal with its Phase 0 governance disclosure, and the non-scored drug-specific risk flags; 'ira-framework' covers the Year-9/Year-13 MFP cliff modeling and the separate IRA classification for expanded modalities such as RNA Therapeutics, Protein Degrader, Radioligand, Oncolytic Virus, and Cancer Vaccine; 'development-paths' covers development-path tiers, automatic-effect policy, and the no path-based PoS/default-multiplier rule; 'stage-normalization' covers exact clinical labels, work packages, canonical PoS gates, and the no label-only PoS modifier rule for Phase 1b/2a/2b, adaptive, pivotal, expansion, platform, bridging, and related labels; 'evidence-standards' covers source tiers and freshness rules; 'network-benchmarks' covers anonymization and cohort cuts; 'cogs-benchmark' covers the per-modality COGS% default bands and price-sensitivity methodology; 'sga-benchmark' covers the per-commercial-model SG&A% default bands (orphan/specialty/primary-care); 'tax-benchmark' covers the US-statutory-21% default tax rate, effective-rate reality, and the NOL cap; 'sec-deal-terms' is the retirement notice for the SEC EDGAR deal-term source (retired 2026-09-27), with its frozen versions."

Changed1 schema field changedJun 23, 2026

changedInput schema / properties / section / description

Previous value: -"Which methodology section to fetch. 'rnpv' covers the core risk-adjusted NPV calculation: cumulative PoS, midpoint-discounted risk-adjusted development costs, the S-curve ramp/plateau/LOE revenue lifecycle net of COGS/SG&A/tax, WACC discounting, the rNPV and Unadjusted-NPV equations, Monte Carlo / expected NPV, and one-at-a-time sensitivity; 'backtest' covers the validation methodology and AUC/CI numbers; 'pos-calibration' covers the indication × modality × biomarker matrix, the eight scored multipliers including the engine 2.6.0 biomarker_quality drug-specific multiplier (oncology solid tumor, Phase II/III), the Phase 1 ORR extracted-but-not-scored signal with its Phase 0 governance disclosure, and the non-scored drug-specific risk flags; 'ira-framework' covers the Year-9/Year-13 MFP cliff modeling; 'development-paths' covers development-path tiers, automatic-effect policy, and the no path-based PoS/default-multiplier rule; 'stage-normalization' covers exact clinical labels, work packages, canonical PoS gates, and the no label-only PoS modifier rule for Phase 1b/2a/2b, adaptive, pivotal, expansion, platform, bridging, and related labels; 'evidence-standards' covers source tiers and freshness rules; 'network-benchmarks' covers anonymization and cohort cuts; 'cogs-benchmark' covers the per-modality COGS% default bands and price-sensitivity methodology; 'sga-benchmark' covers the per-commercial-model SG&A% default bands (orphan/specialty/primary-care); 'tax-benchmark' covers the US-statutory-21% default tax rate, effective-rate reality, and the NOL cap; 'sec-deal-terms' covers the SEC EDGAR 8-K Item 1.01 deal-term extraction pipeline (cohort, extractor + classifier versions, fields extracted, v0 vs v1 scope)."New value: +"Which methodology section to fetch. 'rnpv' covers the core risk-adjusted NPV calculation: cumulative PoS, midpoint-discounted risk-adjusted development costs, the S-curve ramp/plateau/LOE revenue lifecycle net of COGS/SG&A/tax, WACC discounting, the rNPV and Unadjusted-NPV equations, Monte Carlo / expected NPV, and one-at-a-time sensitivity; 'backtest' covers the validation methodology and AUC/CI numbers; 'pos-calibration' covers the indication × modality × biomarker matrix, expanded modality normalization into the eight benchmark baselines, the scored multipliers including the engine 2.6.0 biomarker_quality drug-specific multiplier (oncology solid tumor, Phase II/III), the Phase 1 ORR extracted-but-not-scored signal with its Phase 0 governance disclosure, and the non-scored drug-specific risk flags; 'ira-framework' covers the Year-9/Year-13 MFP cliff modeling and the separate IRA classification for expanded modalities such as RNA Therapeutics, Protein Degrader, Radioligand, Oncolytic Virus, and Cancer Vaccine; 'development-paths' covers development-path tiers, automatic-effect policy, and the no path-based PoS/default-multiplier rule; 'stage-normalization' covers exact clinical labels, work packages, canonical PoS gates, and the no label-only PoS modifier rule for Phase 1b/2a/2b, adaptive, pivotal, expansion, platform, bridging, and related labels; 'evidence-standards' covers source tiers and freshness rules; 'network-benchmarks' covers anonymization and cohort cuts; 'cogs-benchmark' covers the per-modality COGS% default bands and price-sensitivity methodology; 'sga-benchmark' covers the per-commercial-model SG&A% default bands (orphan/specialty/primary-care); 'tax-benchmark' covers the US-statutory-21% default tax rate, effective-rate reality, and the NOL cap; 'sec-deal-terms' covers the SEC EDGAR 8-K Item 1.01 deal-term extraction pipeline (cohort, extractor + classifier versions, fields extracted, v0 vs v1 scope)."

Changed2 schema fields changedJun 19, 2026

changedInput schema / properties / section / description

Previous value: -"Which methodology section to fetch. 'rnpv' covers the core risk-adjusted NPV calculation: cumulative PoS, midpoint-discounted risk-adjusted development costs, the S-curve ramp/plateau/LOE revenue lifecycle net of COGS/SG&A/tax, WACC discounting, the rNPV and Unadjusted-NPV equations, Monte Carlo / expected NPV, and one-at-a-time sensitivity; 'backtest' covers the validation methodology and AUC/CI numbers; 'pos-calibration' covers the indication × modality × biomarker matrix, the eight scored multipliers including the engine 2.6.0 biomarker_quality drug-specific multiplier (oncology solid tumor, Phase II/III), the Phase 1 ORR extracted-but-not-scored signal with its Phase 0 governance disclosure, and the non-scored drug-specific risk flags; 'ira-framework' covers the Year-9/Year-13 MFP cliff modeling; 'development-paths' covers development-path tiers, automatic-effect policy, and the no path-based PoS/default-multiplier rule; 'evidence-standards' covers source tiers and freshness rules; 'network-benchmarks' covers anonymization and cohort cuts; 'cogs-benchmark' covers the per-modality COGS% default bands and price-sensitivity methodology; 'sga-benchmark' covers the per-commercial-model SG&A% default bands (orphan/specialty/primary-care); 'tax-benchmark' covers the US-statutory-21% default tax rate, effective-rate reality, and the NOL cap; 'sec-deal-terms' covers the SEC EDGAR 8-K Item 1.01 deal-term extraction pipeline (cohort, extractor + classifier versions, fields extracted, v0 vs v1 scope)."New value: +"Which methodology section to fetch. 'rnpv' covers the core risk-adjusted NPV calculation: cumulative PoS, midpoint-discounted risk-adjusted development costs, the S-curve ramp/plateau/LOE revenue lifecycle net of COGS/SG&A/tax, WACC discounting, the rNPV and Unadjusted-NPV equations, Monte Carlo / expected NPV, and one-at-a-time sensitivity; 'backtest' covers the validation methodology and AUC/CI numbers; 'pos-calibration' covers the indication × modality × biomarker matrix, the eight scored multipliers including the engine 2.6.0 biomarker_quality drug-specific multiplier (oncology solid tumor, Phase II/III), the Phase 1 ORR extracted-but-not-scored signal with its Phase 0 governance disclosure, and the non-scored drug-specific risk flags; 'ira-framework' covers the Year-9/Year-13 MFP cliff modeling; 'development-paths' covers development-path tiers, automatic-effect policy, and the no path-based PoS/default-multiplier rule; 'stage-normalization' covers exact clinical labels, work packages, canonical PoS gates, and the no label-only PoS modifier rule for Phase 1b/2a/2b, adaptive, pivotal, expansion, platform, bridging, and related labels; 'evidence-standards' covers source tiers and freshness rules; 'network-benchmarks' covers anonymization and cohort cuts; 'cogs-benchmark' covers the per-modality COGS% default bands and price-sensitivity methodology; 'sga-benchmark' covers the per-commercial-model SG&A% default bands (orphan/specialty/primary-care); 'tax-benchmark' covers the US-statutory-21% default tax rate, effective-rate reality, and the NOL cap; 'sec-deal-terms' covers the SEC EDGAR 8-K Item 1.01 deal-term extraction pipeline (cohort, extractor + classifier versions, fields extracted, v0 vs v1 scope)."

changedInput schema / properties / section / enum

Previous value: -[
-  "rnpv",
-  "backtest",
-  "pos-calibration",
-  "ira-framework",
-  "development-paths",
-  "evidence-standards",
-  "network-benchmarks",
-  "cogs-benchmark",
-  "sga-benchmark",
-  "tax-benchmark",
-  "sec-deal-terms"
-]New value: +[
+  "rnpv",
+  "backtest",
+  "pos-calibration",
+  "ira-framework",
+  "development-paths",
+  "stage-normalization",
+  "evidence-standards",
+  "network-benchmarks",
+  "cogs-benchmark",
+  "sga-benchmark",
+  "tax-benchmark",
+  "sec-deal-terms"
+]

Changed3 schema fields changedJun 19, 2026

changedInput schema / properties / section / description

Previous value: -"Which methodology section to fetch. 'backtest' covers the validation methodology and AUC/CI numbers; 'pos-calibration' covers the indication × modality × biomarker matrix, the eight scored multipliers including the engine 2.6.0 biomarker_quality drug-specific multiplier (oncology solid tumor, Phase II/III), the Phase 1 ORR extracted-but-not-scored signal with its Phase 0 governance disclosure, and the non-scored drug-specific risk flags; 'ira-framework' covers the Year-9/Year-13 MFP cliff modeling; 'development-paths' covers development-path tiers, automatic-effect policy, and the no path-based PoS/default-multiplier rule; 'evidence-standards' covers source tiers and freshness rules; 'network-benchmarks' covers anonymization and cohort cuts; 'cogs-benchmark' covers the per-modality COGS% default bands and price-sensitivity methodology; 'sga-benchmark' covers the per-commercial-model SG&A% default bands (orphan/specialty/primary-care); 'tax-benchmark' covers the US-statutory-21% default tax rate, effective-rate reality, and the NOL cap; 'sec-deal-terms' covers the SEC EDGAR 8-K Item 1.01 deal-term extraction pipeline (cohort, extractor + classifier versions, fields extracted, v0 vs v1 scope)."New value: +"Which methodology section to fetch. 'rnpv' covers the core risk-adjusted NPV calculation: cumulative PoS, midpoint-discounted risk-adjusted development costs, the S-curve ramp/plateau/LOE revenue lifecycle net of COGS/SG&A/tax, WACC discounting, the rNPV and Unadjusted-NPV equations, Monte Carlo / expected NPV, and one-at-a-time sensitivity; 'backtest' covers the validation methodology and AUC/CI numbers; 'pos-calibration' covers the indication × modality × biomarker matrix, the eight scored multipliers including the engine 2.6.0 biomarker_quality drug-specific multiplier (oncology solid tumor, Phase II/III), the Phase 1 ORR extracted-but-not-scored signal with its Phase 0 governance disclosure, and the non-scored drug-specific risk flags; 'ira-framework' covers the Year-9/Year-13 MFP cliff modeling; 'development-paths' covers development-path tiers, automatic-effect policy, and the no path-based PoS/default-multiplier rule; 'evidence-standards' covers source tiers and freshness rules; 'network-benchmarks' covers anonymization and cohort cuts; 'cogs-benchmark' covers the per-modality COGS% default bands and price-sensitivity methodology; 'sga-benchmark' covers the per-commercial-model SG&A% default bands (orphan/specialty/primary-care); 'tax-benchmark' covers the US-statutory-21% default tax rate, effective-rate reality, and the NOL cap; 'sec-deal-terms' covers the SEC EDGAR 8-K Item 1.01 deal-term extraction pipeline (cohort, extractor + classifier versions, fields extracted, v0 vs v1 scope)."

changedInput schema / properties / section / enum

Previous value: -[
-  "backtest",
-  "pos-calibration",
-  "ira-framework",
-  "development-paths",
-  "evidence-standards",
-  "network-benchmarks",
-  "cogs-benchmark",
-  "sga-benchmark",
-  "tax-benchmark",
-  "sec-deal-terms"
-]New value: +[
+  "rnpv",
+  "backtest",
+  "pos-calibration",
+  "ira-framework",
+  "development-paths",
+  "evidence-standards",
+  "network-benchmarks",
+  "cogs-benchmark",
+  "sga-benchmark",
+  "tax-benchmark",
+  "sec-deal-terms"
+]

changedOutput schema / properties / data / properties / section_id / enum

Previous value: -[
-  "backtest",
-  "pos-calibration",
-  "ira-framework",
-  "development-paths",
-  "evidence-standards",
-  "network-benchmarks",
-  "cogs-benchmark",
-  "sga-benchmark",
-  "tax-benchmark",
-  "sec-deal-terms"
-]New value: +[
+  "rnpv",
+  "backtest",
+  "pos-calibration",
+  "ira-framework",
+  "development-paths",
+  "evidence-standards",
+  "network-benchmarks",
+  "cogs-benchmark",
+  "sga-benchmark",
+  "tax-benchmark",
+  "sec-deal-terms"
+]

Changed3 schema fields changedJun 17, 2026

changedInput schema / properties / section / description

Previous value: -"Which methodology section to fetch. 'backtest' covers the validation methodology and AUC/CI numbers; 'pos-calibration' covers the indication × modality × biomarker matrix, the eight scored multipliers including the engine 2.6.0 biomarker_quality drug-specific multiplier (oncology solid tumor, Phase II/III), the Phase 1 ORR extracted-but-not-scored signal with its Phase 0 governance disclosure, and the non-scored drug-specific risk flags; 'ira-framework' covers the Year-9/Year-13 MFP cliff modeling; 'evidence-standards' covers source tiers and freshness rules; 'network-benchmarks' covers anonymization and cohort cuts; 'cogs-benchmark' covers the per-modality COGS% default bands and price-sensitivity methodology; 'sga-benchmark' covers the per-commercial-model SG&A% default bands (orphan/specialty/primary-care); 'tax-benchmark' covers the US-statutory-21% default tax rate, effective-rate reality, and the NOL cap; 'sec-deal-terms' covers the SEC EDGAR 8-K Item 1.01 deal-term extraction pipeline (cohort, extractor + classifier versions, fields extracted, v0 vs v1 scope)."New value: +"Which methodology section to fetch. 'backtest' covers the validation methodology and AUC/CI numbers; 'pos-calibration' covers the indication × modality × biomarker matrix, the eight scored multipliers including the engine 2.6.0 biomarker_quality drug-specific multiplier (oncology solid tumor, Phase II/III), the Phase 1 ORR extracted-but-not-scored signal with its Phase 0 governance disclosure, and the non-scored drug-specific risk flags; 'ira-framework' covers the Year-9/Year-13 MFP cliff modeling; 'development-paths' covers development-path tiers, automatic-effect policy, and the no path-based PoS/default-multiplier rule; 'evidence-standards' covers source tiers and freshness rules; 'network-benchmarks' covers anonymization and cohort cuts; 'cogs-benchmark' covers the per-modality COGS% default bands and price-sensitivity methodology; 'sga-benchmark' covers the per-commercial-model SG&A% default bands (orphan/specialty/primary-care); 'tax-benchmark' covers the US-statutory-21% default tax rate, effective-rate reality, and the NOL cap; 'sec-deal-terms' covers the SEC EDGAR 8-K Item 1.01 deal-term extraction pipeline (cohort, extractor + classifier versions, fields extracted, v0 vs v1 scope)."

changedInput schema / properties / section / enum

Previous value: -[
-  "backtest",
-  "pos-calibration",
-  "ira-framework",
-  "evidence-standards",
-  "network-benchmarks",
-  "cogs-benchmark",
-  "sga-benchmark",
-  "tax-benchmark",
-  "sec-deal-terms"
-]New value: +[
+  "backtest",
+  "pos-calibration",
+  "ira-framework",
+  "development-paths",
+  "evidence-standards",
+  "network-benchmarks",
+  "cogs-benchmark",
+  "sga-benchmark",
+  "tax-benchmark",
+  "sec-deal-terms"
+]

changedOutput schema / properties / data / properties / section_id / enum

Previous value: -[
-  "backtest",
-  "pos-calibration",
-  "ira-framework",
-  "evidence-standards",
-  "network-benchmarks",
-  "cogs-benchmark",
-  "sga-benchmark",
-  "tax-benchmark",
-  "sec-deal-terms"
-]New value: +[
+  "backtest",
+  "pos-calibration",
+  "ira-framework",
+  "development-paths",
+  "evidence-standards",
+  "network-benchmarks",
+  "cogs-benchmark",
+  "sga-benchmark",
+  "tax-benchmark",
+  "sec-deal-terms"
+]

Changed1 schema field changedMay 27, 2026

changedInput schema / properties / section / description

Previous value: -"Which methodology section to fetch. 'backtest' covers the validation methodology and AUC/CI numbers; 'pos-calibration' covers the indication × modality × biomarker matrix and multipliers; 'ira-framework' covers the Year-9/Year-13 MFP cliff modeling; 'evidence-standards' covers source tiers and freshness rules; 'network-benchmarks' covers anonymization and cohort cuts; 'cogs-benchmark' covers the per-modality COGS% default bands and price-sensitivity methodology; 'sga-benchmark' covers the per-commercial-model SG&A% default bands (orphan/specialty/primary-care); 'tax-benchmark' covers the US-statutory-21% default tax rate, effective-rate reality, and the NOL cap; 'sec-deal-terms' covers the SEC EDGAR 8-K Item 1.01 deal-term extraction pipeline (cohort, extractor + classifier versions, fields extracted, v0 vs v1 scope)."New value: +"Which methodology section to fetch. 'backtest' covers the validation methodology and AUC/CI numbers; 'pos-calibration' covers the indication × modality × biomarker matrix, the eight scored multipliers including the engine 2.6.0 biomarker_quality drug-specific multiplier (oncology solid tumor, Phase II/III), the Phase 1 ORR extracted-but-not-scored signal with its Phase 0 governance disclosure, and the non-scored drug-specific risk flags; 'ira-framework' covers the Year-9/Year-13 MFP cliff modeling; 'evidence-standards' covers source tiers and freshness rules; 'network-benchmarks' covers anonymization and cohort cuts; 'cogs-benchmark' covers the per-modality COGS% default bands and price-sensitivity methodology; 'sga-benchmark' covers the per-commercial-model SG&A% default bands (orphan/specialty/primary-care); 'tax-benchmark' covers the US-statutory-21% default tax rate, effective-rate reality, and the NOL cap; 'sec-deal-terms' covers the SEC EDGAR 8-K Item 1.01 deal-term extraction pipeline (cohort, extractor + classifier versions, fields extracted, v0 vs v1 scope)."

Changed3 schema fields changedMay 25, 2026

changedInput schema / properties / section / description

Previous value: -"Which methodology section to fetch. 'backtest' covers the validation methodology and AUC/CI numbers; 'pos-calibration' covers the indication × modality × biomarker matrix and multipliers; 'ira-framework' covers the Year-9/Year-13 MFP cliff modeling; 'evidence-standards' covers source tiers and freshness rules; 'network-benchmarks' covers anonymization and cohort cuts; 'cogs-benchmark' covers the per-modality COGS% default bands and price-sensitivity methodology; 'sga-benchmark' covers the per-commercial-model SG&A% default bands (orphan/specialty/primary-care); 'tax-benchmark' covers the US-statutory-21% default tax rate, effective-rate reality, and the NOL cap."New value: +"Which methodology section to fetch. 'backtest' covers the validation methodology and AUC/CI numbers; 'pos-calibration' covers the indication × modality × biomarker matrix and multipliers; 'ira-framework' covers the Year-9/Year-13 MFP cliff modeling; 'evidence-standards' covers source tiers and freshness rules; 'network-benchmarks' covers anonymization and cohort cuts; 'cogs-benchmark' covers the per-modality COGS% default bands and price-sensitivity methodology; 'sga-benchmark' covers the per-commercial-model SG&A% default bands (orphan/specialty/primary-care); 'tax-benchmark' covers the US-statutory-21% default tax rate, effective-rate reality, and the NOL cap; 'sec-deal-terms' covers the SEC EDGAR 8-K Item 1.01 deal-term extraction pipeline (cohort, extractor + classifier versions, fields extracted, v0 vs v1 scope)."

changedInput schema / properties / section / enum

Previous value: -[
-  "backtest",
-  "pos-calibration",
-  "ira-framework",
-  "evidence-standards",
-  "network-benchmarks",
-  "cogs-benchmark",
-  "sga-benchmark",
-  "tax-benchmark"
-]New value: +[
+  "backtest",
+  "pos-calibration",
+  "ira-framework",
+  "evidence-standards",
+  "network-benchmarks",
+  "cogs-benchmark",
+  "sga-benchmark",
+  "tax-benchmark",
+  "sec-deal-terms"
+]

changedOutput schema / properties / data / properties / section_id / enum

Previous value: -[
-  "backtest",
-  "pos-calibration",
-  "ira-framework",
-  "evidence-standards",
-  "network-benchmarks",
-  "cogs-benchmark",
-  "sga-benchmark",
-  "tax-benchmark"
-]New value: +[
+  "backtest",
+  "pos-calibration",
+  "ira-framework",
+  "evidence-standards",
+  "network-benchmarks",
+  "cogs-benchmark",
+  "sga-benchmark",
+  "tax-benchmark",
+  "sec-deal-terms"
+]

Changed3 schema fields changedMay 21, 2026

changedInput schema / properties / section / description

Previous value: -"Which methodology section to fetch. 'backtest' covers the validation methodology and AUC/CI numbers; 'pos-calibration' covers the indication × modality × biomarker matrix and multipliers; 'ira-framework' covers the Year-9/Year-13 MFP cliff modeling; 'evidence-standards' covers source tiers and freshness rules; 'network-benchmarks' covers anonymization and cohort cuts; 'cogs-benchmark' covers the per-modality COGS% default bands and price-sensitivity methodology."New value: +"Which methodology section to fetch. 'backtest' covers the validation methodology and AUC/CI numbers; 'pos-calibration' covers the indication × modality × biomarker matrix and multipliers; 'ira-framework' covers the Year-9/Year-13 MFP cliff modeling; 'evidence-standards' covers source tiers and freshness rules; 'network-benchmarks' covers anonymization and cohort cuts; 'cogs-benchmark' covers the per-modality COGS% default bands and price-sensitivity methodology; 'sga-benchmark' covers the per-commercial-model SG&A% default bands (orphan/specialty/primary-care); 'tax-benchmark' covers the US-statutory-21% default tax rate, effective-rate reality, and the NOL cap."

changedInput schema / properties / section / enum

Previous value: -[
-  "backtest",
-  "pos-calibration",
-  "ira-framework",
-  "evidence-standards",
-  "network-benchmarks",
-  "cogs-benchmark"
-]New value: +[
+  "backtest",
+  "pos-calibration",
+  "ira-framework",
+  "evidence-standards",
+  "network-benchmarks",
+  "cogs-benchmark",
+  "sga-benchmark",
+  "tax-benchmark"
+]

changedOutput schema / properties / data / properties / section_id / enum

Previous value: -[
-  "backtest",
-  "pos-calibration",
-  "ira-framework",
-  "evidence-standards",
-  "network-benchmarks",
-  "cogs-benchmark"
-]New value: +[
+  "backtest",
+  "pos-calibration",
+  "ira-framework",
+  "evidence-standards",
+  "network-benchmarks",
+  "cogs-benchmark",
+  "sga-benchmark",
+  "tax-benchmark"
+]

Changed3 schema fields changedMay 20, 2026

changedInput schema / properties / section / description

Previous value: -"Which methodology section to fetch. 'backtest' covers the validation methodology and AUC/CI numbers; 'pos-calibration' covers the indication × modality × biomarker matrix and multipliers; 'ira-framework' covers the Year-9/Year-13 MFP cliff modeling; 'evidence-standards' covers source tiers and freshness rules; 'network-benchmarks' covers anonymization and cohort cuts."New value: +"Which methodology section to fetch. 'backtest' covers the validation methodology and AUC/CI numbers; 'pos-calibration' covers the indication × modality × biomarker matrix and multipliers; 'ira-framework' covers the Year-9/Year-13 MFP cliff modeling; 'evidence-standards' covers source tiers and freshness rules; 'network-benchmarks' covers anonymization and cohort cuts; 'cogs-benchmark' covers the per-modality COGS% default bands and price-sensitivity methodology."

changedInput schema / properties / section / enum

Previous value: -[
-  "backtest",
-  "pos-calibration",
-  "ira-framework",
-  "evidence-standards",
-  "network-benchmarks"
-]New value: +[
+  "backtest",
+  "pos-calibration",
+  "ira-framework",
+  "evidence-standards",
+  "network-benchmarks",
+  "cogs-benchmark"
+]

changedOutput schema / properties / data / properties / section_id / enum

Previous value: -[
-  "backtest",
-  "pos-calibration",
-  "ira-framework",
-  "evidence-standards",
-  "network-benchmarks"
-]New value: +[
+  "backtest",
+  "pos-calibration",
+  "ira-framework",
+  "evidence-standards",
+  "network-benchmarks",
+  "cogs-benchmark"
+]

First observedMay 3, 2026

TDQS

A3.8/5.0

Behavior4/5

Does the description disclose side effects, auth requirements, rate limits, or destructive behavior?

Annotations already declare readOnlyHint, idempotentHint, openWorldHint, and destructiveHint=false, so the safety profile is covered structurally. The description adds genuinely new behavioral context: that each section carries a stable URL and a methodology version identifier suitable for citation. It stops short of describing response format or size, but with a rich annotation set that is a minor omission.

Agents need to know what a tool does to the world before calling it. Descriptions should go beyond structured annotations to explain consequences.

Conciseness3/5

Is the description appropriately sized, front-loaded, and free of redundancy?

Purpose is front-loaded in the opening clause, which is good. But the 14-item parenthetical enumeration of sections is redundant with an enum that already defines each value at length, bloating a single sentence without adding routing value. The second sentence (citation, stable URL, version id) is the most valuable part and could carry more weight.

Shorter descriptions cost fewer tokens and are easier for agents to parse. Every sentence should earn its place.

Completeness4/5

Given the tool's complexity, does the description cover enough for an agent to succeed on first attempt?

For a single-parameter, read-only documentation fetch with an output schema present and full annotation coverage, the description supplies enough for correct invocation: what is retrieved, the citation/version behavior, and the domain of each section. Nothing critical is missing, though the redundancy in the section list inflates length without improving completeness.

Complex tools with many parameters or behaviors need more documentation. Simple tools need less. This dimension scales expectations accordingly.

Parameters3/5

Does the description clarify parameter syntax, constraints, interactions, or defaults beyond what the schema provides?

Schema description coverage is 100% and the single 'section' enum is documented in exhaustive detail inside the schema itself (each value with a paragraph of scope). The description's parenthetical list of sections largely restates the enum values, adding little beyond what the schema provides. Baseline 3 is appropriate when the schema does the heavy lifting.

Input schemas describe structure but not intent. Descriptions should explain non-obvious parameter relationships and valid value ranges.

Purpose5/5

Does the description clearly state what the tool does and how it differs from similar tools?

States a specific verb ('Fetch') and resource ('a PhaseFolio methodology section's full content'), and the parenthetical enumerates the exact domains covered (rNPV, backtest, PoS calibration, IRA framework, etc.). This is clearly distinguishable from siblings like get_dossier, get_evidence, or query_benchmarks, which fetch asset/evidence/benchmark data rather than methodology documentation.

Agents choose between tools based on descriptions. A clear purpose with a specific verb and resource helps agents select the right tool.

Usage Guidelines3/5

Does the description explain when to use this tool, when not to, or what alternatives exist?

The phrase 'Designed for citation' implies the intended use case (retrieving methodology text to reference in analysis output), which is useful contextual framing. However, it never states when to prefer this over siblings such as get_evidence or verify_export, nor any exclusions or prerequisites, leaving the selection logic largely implicit.

Agents often have multiple tools that could apply. Explicit usage guidance like "use X instead of Y when Z" prevents misuse.

All phasefolio tools Inspect

Try in Browser

One endpoint for every MCP toolRayrun runs every MCP server behind one URL and holds the credentials. Each call is decided per client, tool, and argument, then recorded.ray.runAd

Glama MCP Gateway

Add one secure layer between your agents and this server.

Resources

Need Help?